By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.12.12

Sai Nxt

Sai Life Sciences announces Sai Nxt, an initiative to transform the organization into a new generation CDMO

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced Sai Nxt, an organization-wide initiative aimed at transforming the company into a new generation CDMO. Guided by the insights and feedback from its customers, the company is investing upwards of US $ 150 million over the period between 2019 and 2023 as a part of Sai Nxt, with a focus on three key areas :

  1. People & culture
  2. Processes & automation
  3. Infrastructure & scientific capabilities

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “Sai Nxt marks a transformative phase in our journey. Our growth over the years has essentially been driven by our scientific capabilities and customer focus. Raising the bar further, Sai Nxt will help us better serve the growing demand from global innovator pharma and biotech companies for speed and flexibility, with an assurance of compliance and dependability.”

Built on the foundation of partnership, Sai Life Sciences has grown to become one of India’s most trusted CDMOs. Coinciding with the completion of 20 years since its inception, Sai Nxt is the transformative lever aimed to propel the organization in the next phase of its growth.

Sai Nxt initiatives

  1. People & Culture: Expanding scientific talent pool, inducting top-notch global scientific and leadership talent, role-based integrated online training, shop floor transformation, nurturing culture of excellence
  2. Processes & Automation: Process simplification, strengthening governance systems, electronic manufacturing records, IT systems integration, foundation for seamless data capture across operations, leveraging latest technologies (RPA, IOT, AI / ML, AR/ VR) for innovation and intelligence
  3. Infrastructure & Capabilities: Biology lab in Cambridge (MA, USA), Process R&D lab in Manchester (UK), Integrated Discovery and Development campus, expanded suite of technology platforms, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems

Through Sai Nxt, the company aims to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Share article

More News

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more